Raphael Pharmaceutical Inc. financial data

Symbol
RAPH on OTC
Location
Suite 105 5348 Vegas Dr., Las Vegas, NV
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.78 % -91.7%
Return On Equity -8.99K % -329%
Return On Assets -3.57K % -548%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.6M shares +4.95%
Common Stock, Shares, Outstanding 19.6M shares +4.95%
Entity Public Float 17.2M USD +71.6%
Common Stock, Value, Issued 196K USD +4.81%
Weighted Average Number of Shares Outstanding, Basic 19.6M shares +4.95%
Weighted Average Number of Shares Outstanding, Diluted 19.6M shares +4.95%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 497K USD +129%
General and Administrative Expense 888K USD +7.77%
Operating Income (Loss) -1.39M USD -33%
Nonoperating Income (Expense) -16K USD +23.8%
Net Income (Loss) Attributable to Parent -1.4M USD -31.9%
Earnings Per Share, Basic 0 USD/shares +100%
Earnings Per Share, Diluted 0 USD/shares +100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20K USD -83.3%
Other Assets, Current 2K USD -77.8%
Assets, Current 5K USD -89.8%
Property, Plant and Equipment, Net 2K USD 0%
Assets 7K USD -86.3%
Accounts Payable, Current 125K USD +81.2%
Accrued Liabilities, Current 375K USD +1400%
Liabilities, Current 1.27M USD +90.6%
Retained Earnings (Accumulated Deficit) -9.9M USD -17.3%
Stockholders' Equity Attributable to Parent -1.26M USD -105%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -9K USD -109%
Liabilities and Equity 7K USD -86.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -209K USD -21.5%
Net Cash Provided by (Used in) Financing Activities 240K USD +4.35%
Net Cash Provided by (Used in) Investing Activities -1K USD
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 19.6M shares +4.95%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 57K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3K USD -92.5%
Deferred Tax Assets, Valuation Allowance 1.54M USD +21.1%
Deferred Tax Assets, Gross 1.54M USD +21.1%
Depreciation 1K USD
Payments to Acquire Property, Plant, and Equipment 1K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.97M USD +21.3%
Additional Paid in Capital 7.18M USD +52.5%